Stereotactic ablative radiotherapy, also known as stereotactic body radiation therapy, has been developed as an innovative therapy for stage I non-small cell lung cancer and has now emerged as a standard treatment option for medically inoperable patients through careful analysis using prospective multi-institutional trials. We review and update the evidence for use of stereotactic ablative radiotherapy in medically inoperable patients with stage I lung cancer, and its possible extension of use to operable patients, from the perspectives of an experienced radiation oncologist and a thoracic surgeon.
- Early stage
- Non-small cell lung cancer
- Stereotactic ablative radiotherapy
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Cardiology and Cardiovascular Medicine